OBR Daily Commentary


2021 GU Cancers Symposium: Apalutamide Combo Boosts PFS in ACIS Trial of mCRPC

(OBR) Feb 11, 2021 - Combining apalutamide (APA) with abiraterone acetate plus prednisone (AAP) reduced the risk of radiographic progression or death by 31% in patients with advanced prostate cancer who had never received chemotherapy, according to findings presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium. This combination yielded stronger outcomes than AAP alone, especially in certain patient subgroups, said Dana E. Rathkopf, MD, who presented the final results of ACIS, a randomized, double-blind, phase 3 study (Abstract 9) of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Read Article arrow

Tomasz Beer (Posted: February 11, 2021)


This study demonstrated an improvement in progression-free survival but not overall survival with increased toxicity and cost. Because the comparison was between apalutamide + abiraterone and abiraterone alone, we don't know whether apalutamide alone would compare favorably to abiraterone.



Add Comment 1 Comment(s)